GOSS Seralutinib NDA: $0.20 Stock After Phase 3 Failure

Price update August 2, 2026 (Polygon, July 31 close): GOSS closed at $0.17 on July 31, down 15% from the $0.1994 reference price in this article. The stock remains a micro-cap with a market cap under $60 million. The September 2026 NDA submission timeline is unchanged.

Gossamer Bio (NASDAQ: GOSS) closed July 25 at $0.1994 per share. The market cap is $66.5 million. The stock traded above $10 in 2021. It is down 77% from its pre-Phase 3 price after the PROSERA trial missed its primary endpoint in February 2026. On July 27, the company announced two things: it reacquired worldwide rights to seralutinib from Chiesi for a $5 million settlement payment, and it plans to submit an NDA anyway, citing an FDA Pre-NDA Type B meeting where the agency characterized the missed endpoint as a “review issue rather than a filing issue.”

This is a penny stock betting its last chips on a regulatory Hail Mary. The question is whether the FDA’s “review issue” language means what Gossamer’s investors hope it means, or whether it is the regulatory equivalent of “we’ll take your application and then reject it.” It is the latter, and the $0.20 stock price is telling you the same thing. Here is the full picture.

The Failed Phase 3 PROSERA Trial

The Phase 3 PROSERA study enrolled 390 patients with WHO Functional Class II or III PAH, randomized 1:1 to inhaled seralutinib or placebo. The primary endpoint was change in six-minute walk distance (6MWD) from baseline at Week 24.

The result: a placebo-adjusted improvement of +13.3 meters (Hodges-Lehmann estimate, p=0.0320). The prespecified alpha threshold was 0.025. The trial missed. Under the statistical hierarchy, the key secondary endpoints cannot be evaluated for statistical significance because the primary failed.

The +13.3 meter effect is not nothing. It clears the conventional 0.05 threshold. But the 6MWD endpoint in PAH has a well-established clinically meaningful threshold of approximately 30-35 meters, based on FDA historical precedent from prior PAH approvals. A +13.3 meter delta is below that threshold even if it had been statistically significant. The drug showed a numerically positive signal that is both statistically marginal and clinically modest.

The subgroup data is more interesting. In the prespecified intermediate- and high-risk subgroup (REVEAL Lite 2 score >=6, n=234), seralutinib showed a +20.0 meter placebo-adjusted improvement (p=0.0207), with three of four key secondary endpoints achieving p<0.0125. In connective tissue disease-associated PAH (CTD-APAH, n=87), the improvement was +37.0 meters (p=0.0104). NT-proBNP, a key biomarker of right heart stress, dropped 120.4 ng/L vs placebo (p=0.0002) in the overall population. The full PROSERA results are documented on ClinicalTrials.gov (NCT05934526) and in the company’s February 2026 topline press release.

These subgroup signals are real. But they are subgroup signals from a trial that failed its primary endpoint. The FDA has historically been skeptical of post-hoc and subgroup analyses used to support approval after a missed primary endpoint. The agency’s standard position is that the statistical hierarchy exists to control the family-wise error rate, and once the primary fails, the hierarchy is broken.

The Phase 2 TORREY Data: PVR Was the Real Signal

The Phase 2 TORREY trial (86 patients) met its primary endpoint of change in PVR (pulmonary vascular resistance) at Week 24, with a -14.3% placebo-corrected improvement (p=0.0310). The least squares mean difference was -96.1 dynes/cm5. NT-proBNP dropped 408.3 ng/L vs placebo (p=0.0012). The OLE extension showed continued PVR improvement to -143 dynes/cm5 at Week 72 in the seralutinib-continued group.

The problem is that TORREY’s primary endpoint was PVR, and PROSERA’s primary endpoint was 6MWD. Gossamer switched endpoints between Phase 2 and Phase 3, which is a common strategic decision but a risky one. PVR is a hemodynamic measure that directly captures the disease mechanism (pulmonary vascular remodeling). 6MWD is a functional measure that is more variable and influenced by patient motivation, background therapy, and training effects.

The TORREY data showed seralutinib has a real effect on PVR. The PROSERA data showed that effect did not translate to a statistically significant improvement in exercise capacity in the overall population. This is a classic disconnect: the drug does something biologically meaningful but the functional endpoint did not capture it convincingly in the larger trial. The FDA’s “review issue” language may reflect this nuance. The agency is saying the data is reviewable, not that it is approvable.

The Chiesi Deal: What a Pharma Partner Thinks

The Chiesi partnership tells you more about seralutinib’s commercial prospects than any trial data. In 2024, Chiesi licensed ex-US rights to seralutinib for a deal worth up to $486 million in biobucks. On July 27, 2026, Chiesi walked away for a $5 million settlement payment.

A pharma partner that paid $486 million in milestone commitments to exit for $5 million is telling you the drug’s commercial prospects are negligible. Chiesi had access to the full PROSERA dataset, the regulatory correspondence, and the commercial modeling. They ran the numbers and decided that even at zero upfront cost, seralutinib was not worth continuing to develop outside the US. The $5 million is a face-saving payment to unwind the contract cleanly.

This is the single most damning data point in the entire story. Pharma partners do not abandon drugs with real commercial potential over a missed primary endpoint if the subgroup data and biomarker signals support a viable filing. The fact that Chiesi exited rather than supporting the NDA filing tells you the commercial opportunity, even in a best-case approval, does not justify the development cost.

The Regulatory Precedent: Filing After a Missed Primary

The FDA’s characterization of the PROSERA miss as a “review issue rather than a filing issue” is worth parsing carefully. This means the FDA will accept the NDA for substantive review. It does not mean the FDA will approve it.

The precedent for approvals after missed primary endpoints is thin. The most notable case is eteplirsen (Sarepta’s Exondys 51 for DMD), which was approved on a contested endpoint and biomarker data after an AdCom that voted against approval. That approval was controversial, required a Complete Response Letter cycle, and was ultimately granted under accelerated approval. The Sarepta precedent is the exception, not the rule, and it required a patient advocacy pressure campaign and a rare disease population with no alternatives.

Seralutinib is not in the same position. PAH has multiple approved therapies from United Therapeutics (Remodulin, Tyvaso), Johnson and Johnson (Opsumit, Uptravi), and others. The FDA has less urgency to approve a marginal drug in a crowded therapeutic area than it does in a rare disease with no treatments. Gossamer’s NDA will argue that seralutinib offers a novel mechanism (inhaled PDGFR/CSF1R/c-KIT inhibition targeting vascular remodeling) and that the PVR and NT-proBNP data support disease-modifying activity. But the FDA can review those arguments and still issue a CRL citing the missed primary endpoint.

The Valuation: $66 Million Against a $26 Billion Comp

United Therapeutics (UTHR), the dominant PAH company, trades at $527.94 per share with a $26.3 billion market cap (Polygon, July 25). UTHR’s Remodulin generated $526.8 million in 2025 revenue, with Tyvaso DPI contributing additional franchise revenue. United Therapeutics has multiple approved PAH therapies, a commercial infrastructure, and a pipeline. Gossamer Bio has a $0.20 stock, a failed Phase 3, and no revenue.

The comp comparison is almost absurd. UTHR at $26.3 billion with $1.7 billion in annual revenue trades at roughly 15x revenue. Gossamer at $66.5 million is not even a rounding error on UTHR’s market cap. The question for GOSS is not “what is seralutinib worth if approved” but “what is the probability of approval multiplied by the value if approved.”

Even in a generous scenario where the FDA approves seralutinib based on the PROSERA subgroup data and the TORREY PVR data, the peak sales in PAH are modest. The PAH market is approximately $7-8 billion globally and is well-served by existing therapies. A new inhaled drug with a missed primary endpoint and a subgroup-only efficacy signal would face serious commercial headwinds. Peak sales of $200-400 million in a best-case approval scenario, discounted at 90% over the 2-3 years to potential approval, does not justify a meaningful valuation today.

The market is pricing GOSS at $66.5 million, which is essentially the cash value of the company minus liabilities. The stock is trading as a option on the NDA filing, not as a going concern.

The Risk: Dilution and Time

The most immediate risk for GOSS shareholders is dilution. At $0.20 per share with 488.8 million shares outstanding, any capital raise will be massively dilutive. The company needs cash to fund the NDA submission and any subsequent FDA review process. The $5 million Chiesi settlement payment is a token amount. Gossamer will need to raise capital, and at $0.20 per share, the only way to do that is by issuing enormous numbers of shares.

A reverse stock split is almost certain to maintain Nasdaq listing compliance. Nasdaq requires a minimum bid price of $1.00. GOSS at $0.20 is well below that threshold and will receive a delisting notice if it has not already. A reverse split, typically 1-for-10 or 1-for-20, would mechanically raise the price but does nothing for the underlying value.

The timeline risk is also severe. NDA submission is planned for late 2026 or early 2027. FDA review under standard review is 10-12 months, meaning a decision would come in late 2027 or early 2028. That is 18-24 months of cash burn at a company with a $66 million market cap and no revenue. The probability of a Complete Response Letter is high, and a CRL would likely be terminal for the company.

The Verdict

Gossamer Bio at $0.20 is what it looks like: a company whose pipeline partner walked away for pennies, whose Phase 3 missed its primary endpoint, and whose only path forward is a regulatory long shot. The FDA’s “review issue” language is not a guarantee of anything. It is the agency saying it will look at the application, which is what the FDA does. The historical approval rate for NDAs filed after a missed Phase 3 primary endpoint is low, and seralutinib is in a competitive PAH market where the FDA has less incentive to accept marginal data.

I am not buying GOSS at $0.20. The risk-reward does not work. Even if the NDA is accepted for review, the stock will face dilution from capital raises, a reverse split to maintain listing, and 18-24 months of binary regulatory risk. If the FDA approves, the peak sales in a crowded PAH market do not justify a meaningful multiple on today’s enterprise value. If the FDA issues a CRL, the stock goes to zero or near zero.

The one scenario that could work is an approval restricted to the CTD-APAH subgroup, where the +37.0 meter 6MWD effect (p=0.0104) is both clinically meaningful and statistically significant. But that is a narrow indication in a small subpopulation, and the FDA has not signaled willingness to do a restricted-label approval based on a post-hoc subgroup from a failed trial. That scenario is worth monitoring but not worth betting on at current prices.

For investors interested in the PAH space, United Therapeutics at $528 is the comp to watch, not Gossamer. For investors interested in the broader biotech regulatory risk framework, our guide to trading FDA catalysts covers how to position for binary regulatory events. Gossamer Bio is a cautionary tale about what happens when a biotech switches endpoints between Phase 2 and Phase 3 and the second endpoint does not cooperate. The $0.20 stock price is the market’s verdict, and I agree with it.